MED vs HRB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 10, 2026

MED

47.5
AI Score
VS
MED Wins

HRB

30.3
AI Score

Investment Advisor Scores

MED

48score
Recommendation
HOLD

HRB

30score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED HRB Winner
Revenue 152.43M 2.80B HRB
Net Income -5.22M 439.92M HRB
Net Margin -3.4% 15.7% HRB
ROE -2.7% -1805.0% MED
ROA -2.0% 13.0% HRB
Total Assets 260.40M 3.39B HRB
Cash 71.91M 867.01M HRB
Current Ratio 4.86 1.00 MED
Free Cash Flow -108,000 519.57M HRB

Relative Price Performance (Last 90 Days)

MED 1M: +3.9% · 3M: +1.0% HRB 1M: -16.7% · 3M: +25.7%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.4% over 20 days), RSI 53

RSI (14): 52.8 · Price: $12.04

HRB

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 36.2 · Price: $45.12

Fundamentals Snapshot

Metric MED HRB
Market Cap
Forward P/E -43.0 6.8
Trailing P/E 7.9
Revenue (TTM)
Revenue Growth -0.3% 0.0%
Gross Margin 0.7% 0.4%
Operating Margin -0.1% 0.3%
EPS -2.31 5.66
Dividend Yield 0.04%

Frequently Asked Questions

Based on our detailed analysis, MED is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.